- Home
- MDRR vs ALLR Comparison
MDRR vs ALLR Comparison
Compare MDRR & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDRR
- ALLR
- Stock Information
- Founded
- MDRR 2015
- ALLR 2004
- Country
- MDRR United States
- ALLR United States
- Employees
- MDRR N/A
- ALLR N/A
- Industry
- MDRR Real Estate Investment Trusts
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- MDRR Real Estate
- ALLR Health Care
- Exchange
- MDRR Nasdaq
- ALLR Nasdaq
- Market Cap
- MDRR 18.0M
- ALLR 20.2M
- IPO Year
- MDRR 2018
- ALLR N/A
- Fundamental
- Price
- MDRR $13.00
- ALLR $1.11
- Analyst Decision
- MDRR
- ALLR Strong Buy
- Analyst Count
- MDRR 0
- ALLR 1
- Target Price
- MDRR N/A
- ALLR $9.25
- AVG Volume (30 Days)
- MDRR 663.0
- ALLR 292.9K
- Earning Date
- MDRR 11-11-2025
- ALLR 11-14-2025
- Dividend Yield
- MDRR 2.08%
- ALLR N/A
- EPS Growth
- MDRR N/A
- ALLR N/A
- EPS
- MDRR N/A
- ALLR N/A
- Revenue
- MDRR $9,649,145.00
- ALLR N/A
- Revenue This Year
- MDRR N/A
- ALLR N/A
- Revenue Next Year
- MDRR N/A
- ALLR N/A
- P/E Ratio
- MDRR N/A
- ALLR N/A
- Revenue Growth
- MDRR N/A
- ALLR N/A
- 52 Week Low
- MDRR $9.55
- ALLR $0.61
- 52 Week High
- MDRR $15.00
- ALLR $2.35
- Technical
- Relative Strength Index (RSI)
- MDRR 47.68
- ALLR 32.25
- Support Level
- MDRR $13.01
- ALLR $1.34
- Resistance Level
- MDRR $13.45
- ALLR $1.45
- Average True Range (ATR)
- MDRR 0.13
- ALLR 0.09
- MACD
- MDRR -0.11
- ALLR -0.03
- Stochastic Oscillator
- MDRR 28.57
- ALLR 10.37
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.